Trials / Unknown
UnknownNCT05317325
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
A Translational Study of Tumor Antigen-pulsed Dendritic Cell Vaccine for Esophageal Squamous Cell Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | OCDC vaccine; NeoDC vaccine | OCDC vaccine and NeoDC vaccine are administered in a prime-boost regimen by subcutaneous injection. |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2023-12-30
- Completion
- 2024-04-01
- First posted
- 2022-04-07
- Last updated
- 2022-04-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05317325. Inclusion in this directory is not an endorsement.